CytoMed Therapeutics Reports 1H 2023 Financial Report And Provides Corporate Update; Cash And Cash Equivalents: As Of June 30, 2023, The Company Had Cash And Cash Equivalents Of $7.72M
CytoMed Therapeutics Reports 1H 2023 Financial Report And Provides Corporate Update; Cash And Cash Equivalents: As Of June 30, 2023, The Company Had Cash And Cash Equivalents Of $7.72M
Financial Results for the Six Months Ended June 30, 2023
截至2023年6月30日的六個月財務業績
Net Loss: For the six months ended June 30, 2023, the Company's unaudited net loss amounted to S$1.16M ($860,695) excluding expenses related to its NASDAQ Initial Public Offering (IPO) in April 2023 and the costs associated with being a public listed company, compared to S$936,377 for the six months ended 2022.
淨虧損：在截至2023年6月30日的六個月中，公司未經審計的淨虧損爲116萬新元（合860,695美元），其中不包括與2023年4月納斯達克首次公開募股（IPO）相關的費用以及與上市公司相關的成本，而截至2022年的六個月中，淨虧損爲936,377新元。
Cash and Cash Equivalents: As of June 30, 2023, the Company had cash and cash equivalents of S$10.44M ($7.72M). Over the course of the last six months, the Company raised S$12.94M ($9.57M) gross proceeds from the IPO.
現金及現金等價物：截至2023年6月30日，該公司的現金及現金等價物爲1044萬新元（合772萬美元）。在過去的六個月中，該公司從首次公開募股中籌集了1294萬新元（合957萬美元）的總收益。
R&D Expenses: The Company's research and development expenses were S$811,319 ($599,955) and S$604,043 for the six months ended June 30, 2023, and 2022, respectively. This was primarily due to the clinical progress achieved over the last six months.
研發費用：截至2023年6月30日和2022年6月30日的六個月，該公司的研發費用分別爲811,319新元（合599,955美元）和604,043新元。這主要是由於在過去六個月中取得的臨床進展。
G&A Expenses: The Company's general and administrative expenses were S$1.50M ($1.11M) and S$306,457 for the six months ended June 30, 2023, and 2022, respectively. The increase was primarily driven by non-recurring IPO expenses and the costs associated with being a public listed company.
併購費用：截至2023年6月30日和2022年6月30日的六個月，公司的一般和管理費用分別爲150萬新元（合111萬美元）和306,457新元。增長主要是由非經常性IPO支出以及與上市公司相關的成本推動的。
譯文內容由第三人軟體翻譯。